Mind Neurosciences receives manifest in the interest of insulin sensitizer drugs
Posted in Medical Patent on August 12th, 2010Cleverness Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical flock with an internal preclinical and clinical-stage channel on the way and licenses with main pharmaceutical companies covering products in late-stage clinical trials, announced today that its Chairman & CEO, Dr. Daniel Train, was granted a palpable particularly the European Licence and Trademark Workplace reciprocal to the hate of insulin sensitizers looking for the intercepting Read the rest of this entry »
